Glactiv sitagliptin regulatory update

Ono said Japan updated the label of Glactiv sitagliptin to replace a contraindication warning against the use of the diabetes drug in patients with severe renal insufficiency with a precaution for careful administration in those patients. Ono said the contraindication was removed as a result of the June approval of a modified 25 mg tablet of Glactiv with a break line, which allows for the delivery of a 12.5 mg dose. ...